(R)-(-)-Ibuprofen - CAS 51146-57-7
Not Intended for Therapeutic Use. For research use only.
Product Name:
Catalog Number:
CAS Number:
An inhibitor of Cox-1 and Cox-2;A nonsteroidal anti-inflammatory drug
Molecular Weight:
10 mM in DMSO
Molecular Formula:
Quality Standard:
Canonical SMILES:
Cox-2 | COX
Chemical Structure
CAS 51146-57-7 (R)-(-)-Ibuprofen

Related Cox-2 Products

CAS 220991-20-8 Lumiracoxib

(CAS: 220991-20-8)

A novel, selective COX-2 inhibitor; Phase 4

CAS 68767-14-6 Loxoprofen

(CAS: 68767-14-6)

Loxoprofen is a non-steroidal anti-inflammatory drug in the propionic acid derivatives group, which also includes ibuprofen and naproxen among others. It is a n...

CAS 123663-49-0 Iguratimod

(CAS: 123663-49-0)

Iguratimod(T-614) is a selective inhibitor of cyclo-oxygenase-2 (COX-2), and inhibits the production of interleukin-1 (IL-1), IL-6, IL-8 and tumour necrosis fac...

CAS 123653-11-2 NS 398

NS 398
(CAS: 123653-11-2)

A selective COX-2 inhibitor

CAS 78281-72-8 Nepafenac

(CAS: 78281-72-8)

An inhibitor of COX-1 and COX-2

Celecoxib Impurity 3
(CAS: 170569-87-6)

A selective COX-2 inhibitor; A celecoxib analog

CAS 78213-16-8 Diclofenac Diethylamine

Diclofenac Diethylamine
(CAS: 78213-16-8)

Diclofenac diethylamine is a nonsteroidal anti-inflammatory drug taken to reduce inflammation and as an analgesic reducing pain in certain conditions.

FR 122047 hydrochloride
(CAS: 130717-51-0)

FR-122047 is a selective cyclooxygenase-1 (COX-1) inhibitor with IC50 values is 0.028μM for COX-1 and 65 μM for COX-2. FR-122047 displays 2300 fold greater sele...

CAS 70374-39-9 Lornoxicam

(CAS: 70374-39-9)

A non-steroidal COX-1/COX-2 inhibitor; A nonsteroidal anti-inflammatory drug

N-(4-acetamidophenyl)-Indomethacin amide
(CAS: 261766-23-8)

An elective reversible inhibitors of COX-2

CAS 53-86-1 Indomethacin

(CAS: 53-86-1)

A nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively

CAS 51146-57-7 (R)-(-)-Ibuprofen

(CAS: 51146-57-7)

An inhibitor of Cox-1 and Cox-2;A nonsteroidal anti-inflammatory drug

CAS 198470-85-8 Parecoxib Sodium

Parecoxib Sodium
(CAS: 198470-85-8)

The prodrug Parecoxib as well as its active metabolite val have a specific affinity to the cannabinoid (CB) receptor measured in CB1-expressing HEK 293 cells an...

CAS 202409-33-4 Etoricoxib

(CAS: 202409-33-4)

A selective COX-2 inhibitor

CAS 6385-02-0 Meclofenamate Sodium

Meclofenamate Sodium
(CAS: 6385-02-0)

A dual COX-1/COX-2 inhibitor with IC50 of 40 nM and 50 nM, respectively

CAS 61-68-7 Mefenamic Acid

Mefenamic Acid
(CAS: 61-68-7)

A competitive inhibitor of COX-1 and COX-2

BTB 02472
(CAS: 1177728-24-3)

An active-site-targeting Cox-2 inhibitor

COX-2 Inhibitor I
(CAS: 416901-58-1)

An inhibitor of Cox-2

CAS 169590-42-5 Celecoxib

(CAS: 169590-42-5)

A highly selective COX-2 inhibitor

CAS 51803-78-2 Nimesulide

(CAS: 51803-78-2)

A selective COX-2 inhibitor

Reference Reading

1.Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke.
Gonzalez-Valcarcel J1, Sissani L1, Labreuche J1, Bousser MG1, Chamorro A1, Fisher M1, Ford I1, Fox KM1, Hennerici MG1, Mattle HP1, Rothwell PM1, Steg PG1, Vicaut E1, Amarenco P2; PERFORM Investigators. Stroke. 2016 Apr;47(4):1045-52. doi: 10.1161/STROKEAHA.115.012091. Epub 2016 Mar 15.
BACKGROUND AND PURPOSE: The presumed safety of paracetamol in high-cardiovascular risk patients has been questioned. We determined whether paracetamol or ibuprofen use is associated with major cardiovascular events (MACE) or major bleeding in 19 120 patients with recent ischemic stroke or transient ischemic attack of mainly atherothrombotic origin included in the Prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) trial.
2.Indomethacin inhibits tetrodotoxin-resistant Na+ channels at acidic pH in rat nociceptive neurons.
Nakamura M1, Jang IS2. Neuropharmacology. 2016 Feb 17;105:454-462. doi: 10.1016/j.neuropharm.2016.02.017. [Epub ahead of print]
Non-steroidal anti-inflammatory drugs (NSAIDs) are well-known inhibitors of cyclooxygenases (COXs) and are widely used for the treatment of inflammatory pain; however several NSAIDs display COX-independent analgesic action including the inhibition of voltage-gated Na+ channels expressed in primary afferent neurons. In the present study, we examined whether NSAIDs modulate tetrodotoxin-resistant (TTX-R) Na+ channels and if this modulation depends on the extracellular pH. The TTX-R Na+ currents were recorded from small-sized trigeminal ganglion neurons by using a whole-cell patch clamp technique. Among eight NSAIDs tested in this study, several drugs, including aspirin and ibuprofen, did not affect TTX-R Na+ channels either at pH 7.4 or at pH 6.0. However, we found that indomethacin, and, to a lesser extent, ibuprofen and naproxen potently inhibited the peak amplitude of TTX-R Na+ currents at pH 6.0. The indomethacin-induced inhibition of TTX-R Na+ channels was more potent at depolarized membrane potentials.
3.In Situ Loading of Drugs into Mesoporous Silica SBA-15.
Wan MM1,2, Li YY1, Yang T2, Zhang T2, Sun XD1, Zhu JH3. Chemistry. 2016 Mar 21. doi: 10.1002/chem.201504532. [Epub ahead of print]
In a new strategy for loading drugs into mesoporous silica, a hydrophilic (heparin) or hydrophobic drug (ibuprofen) is encapsulated directly in a one-pot synthesis by evaporation-induced self-assembly. In situ drug loading significantly cuts down the preparation time and dramatically increases the loaded amount and released fraction of the drug, and appropriate drug additives favor a mesoporous structure of the vessels. Drug loading was verified by FTIR spectroscopy and release tests, which revealed much longer release with a larger amount of heparin or ibuprofen compared to postloaded SBA-15. Besides, the in vitro anticoagulation properties of the released heparin and the biocompatibility of the vessels were carefully assessed, including activated partial thromboplastin time, thrombin time, hemolysis, platelet adhesion experiments, and the morphologies of red blood cells. A concept of new drug-release agents with soft core and hard shell is proposed and offers guidance for the design of novel drug-delivery systems.
4.Granisetron versus Granisetron-Dexamethasone for Prevention of Postoperative Nausea and Vomiting in Pediatric Strabismus Surgery: A Randomized Double-Blind Trial.
Sinha R1, Shende D2, Maitra S3, Kumar N3, Ray BR3, Mohan VK4. Anesthesiol Res Pract. 2016;2016:4281719. doi: 10.1155/2016/4281719. Epub 2016 Jan 26.
Aim. Efficacy of granisetron and combination of granisetron and dexamethasone was evaluated for prevention of postoperative nausea and vomiting (PONV) in children undergoing elective strabismus surgery. Methods. A total of 136 children (1-15 years) were included. Children received either granisetron (40 mcg/kg) [group G] or combination of granisetron (40 mcg/kg) and dexamethasone (150 mcg/kg) [group GD]. Intraoperative fentanyl requirement and incidence and severity of oculocardiac reflex were assessed. PONV severity was assessed for first 24 hours and if score was >2, it was treated with metoclopramide. Postoperative analgesia was administered with intravenous fentanyl and ibuprofen. Results. The demographic profile, muscles operated, and fentanyl requirement were comparable. Complete response to PONV in first 24 hours was observed in 75% (51/68) of children in group G and 76.9% (50/65) of children in group GD, which was comparable statistically (p = 0.